

Experimental 'decoy' protects against SARS-CoV-2 infection



Durable vectored immunoprophylaxis by decoy-expressing AAV vectors. (*A*) Balb/c mice (n = 3) were injected i.n. with decoy-luciferase fusion proteinexpressing AAV vectors (1×10^{12} vg). Luciferase activity was visualized by live imaging over 60 d at the indicated time points. Representative images of a mouse from each group are shown. (*B*) Luciferase activity in lung tissue homogenates from mice treated with the decoy-luciferase-expressing AAV vectors (n = 2) was measured over the time course. (*C*) The experimental scheme to test the durability of AAV vectored immunoprophylaxis is diagrammed (*Left*). hACE2



K18 Tg (n = 4) were injected with AAV decoy. At 1-, 2-, 3-dpi, the mice were challenged with SARS-CoV-2 (2 × 10⁴ PFU) and viral RNA in the lungs was quantified. The results are shown as a histogram (*Right*). SARS-CoV-2-infected/AAV-untreated (No AAV) and AAV-untreated/SARS-CoV-2-uninfected (Uninfected) controls are shown. CIs are shown as mean \pm SD. *****P* ≤ 0.0001. Credit: *Proceedings of the National Academy of Sciences* (2023). DOI: 10.1073/pnas.2303509120

An experimental "decoy" has provided long-term protection from infection by the pandemic virus in mice, a new study finds.

Led by researchers at NYU Grossman School of Medicine, the work is based on how the <u>virus</u> that causes COVID-19, SARS-CoV-2, uses its <u>spike protein</u> to attach to a protein on the surface of the cells that line human lungs. Once attached to this <u>cell surface protein</u>, called angiotensin converting enzyme 2 (ACE2), the virus spike pulls the cell close, enabling the virus to enter the cell and hijack its machinery to make viral copies.

Earlier in the pandemic, pharmaceutical companies designed monoclonal antibodies to glom onto the spike and neutralize the virus. Treatment of patients soon after infection was successful in preventing hospitalization and death. However the virus rapidly evolved through random genetic changes (mutations) that altered the spike's shape enough to evade even combinations of therapeutic monoclonal antibodies. Thus, such antibodies, which neutralized early variants, became about 300 times less effective against more recent delta and omicron variants.

Published online this week in the *Proceedings of the National Academy of Sciences*, the study describes an alternative approach from which the virus cannot escape. It employs a version of ACE2, the surface protein to which the virus attaches, which unlike the natural, cell-bound version,



is untethered from the cell surface. The free-floating "decoy" binds to the virus by its spikes so that it can no longer attach to ACE2 on cells in airways. Unlike the monoclonal antibodies, which are shaped to interfere with a certain spike shape, the decoy mimics the spike's main target, and the virus cannot easily evolve away from binding to ACE2 and still invade cells.

Treatment with the decoy, either by injection or droplets in the nose, protected 100% of the study mice when they were infected in the lab with an otherwise lethal dose of SARS-CoV-2. The decoy lowered the virus load in the mice 100,000-fold, while mice exposed to a non-active control treatment died. Decoy treatment of mice that were already infected with SARS-CoV-2 caused a rapid drop in viral levels and return to health. This suggests that the decoy could be effective as a therapy post-infection, similar to monoclonal antibodies, the researchers say.

"What is remarkable about our study is that we delivered the decoy using a harmless, adeno-associated virus or AAV vector, a type of gene therapy that has been found in previous studies to be safe for use in humans," says senior study author Nathanial Landau, Ph.D., professor in the Department of Microbiology at NYU Langone Health. "The viral vector instructs cells in the body to produce the decoy so that the mouse or person is protected long-term, without the need for continual treatment." Administered the vector, says Landau, the treatment caused cells not only to make the decoy, but to continue making it for several months, and potentially for years.

Importantly, vaccines traditionally include harmless parts of a virus they are meant to protect against, which trigger a protective immune response should a person later be exposed. Vaccines are less effective, however, if a person's immune system has been compromised by diseases like cancer, or in transplant patients treated with drugs that suppress the immune response to vaccination. Decoy approaches could be very



valuable for immunocompromised patients globally, adds Landau.

Future pandemics

For the new study, the research team made key changes to a free ACE2 receptor molecule, and then fused the spike-binding part of it to the tail end of an antibody with the goal of strengthening its antiviral effect. Attaching ACE2 to the antibody fragment to form what the team calls an "ACE2 microbody" increases the time that the molecule persists in tissues (its half-life). The combination also causes the molecules to form dimers, mirror-image molecular pairs that increase the strength with which the decoy attaches to the viral spike.

Whether administered via injection into muscle, or through droplets in the <u>nasal cavity</u>, the study's AAV vectors provided mice with longlasting protection COVID infection, including the current omicron variants.

The approach promises to be effective even if another coronavirus, a type of virus common in birds and bats or apes, were to be transferred to humans in the future, an event termed "zoonosis." As long as the future virus also uses ACE2 to target cells, the decoy would be ready for "off-the-shelf" soon after an outbreak. If the virus were to somehow switch its receptor a different protein on the surface of lung cells, the decoy could be modified to target the new virus, says Landau.

Along with Landau, the study authors were Takuya Tada and Julia Minnee in the Department of Microbiology at NYU Grossman School of Medicine.

More information: Takuya Tada et al, Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model, *Proceedings of the National Academy of Sciences* (2023). DOI:



10.1073/pnas.2303509120

Provided by NYU Langone Health

Citation: Experimental 'decoy' protects against SARS-CoV-2 infection (2023, May 30) retrieved 26 June 2024 from https://medicalxpress.com/news/2023-05-experimental-decoy-sars-cov-infection.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.